NVLX: Low Level of Toxicity a Major Plus for Nuvilex’

Investment and Company Research
Opportunity Research
HOT TOPICS
 

June 5, 2013

Low Level of Toxicity a Major Plus for Nuvilex

As Nuvilex Inc. (QTCQB - NVLX - $0.14 - Spec Buy) management can attest, scientists and clinicians often approach drug development and treatment very differently.

When academicians and scientists engage in research and studies to treat deadly or highly infectious diseases, the degree of efficacy and mechanism of action are two key elements in which they focus attention. After all, to a great degree, the long term success or the potential outcome of the ongoing research and tests are largely based upon these factors.

On the other hand, clinicians, who are the first line of defense via personal relationships with their patients, weigh quality of life and toxicity as well as efficacy when prescribing treatment for deadly diseases. This fact is best exemplified with the clinician's approach to cancer treatment. In fact it could be one of the key reasons why if ultimately approved the use of Nuvilex's pancreatic cancer treatment approach may emerge as one of the disease's treatments of choice.

The results of its Phase II trial of 14 patients demonstrated that the patients' median survival rate doubled compared to historical control and results of the current gold standard used today, which is Gemzar®. Plus, the 1-year survival rate was triple that of control and double that of the standard Gemzar® therapy. Perhaps the most telling component of the trial was the fact that only one-third of the standard chemotherapy dosage was used, thereby measurably increasing the patient quality of life.

For example, according to the Gemzar.com website, the side effects of using the treatment for pancreatic cancer are many, with varying ranges of severity. On the mild side, nausea, diarrhea, fever and hair loss are common in anywhere from 3:10 to 7:10 of patients. In addition, 7 out of 10 patients suffered from anemia, low white blood cell count, and changes in their liver function tests.

In future tests, Nuvilex will likely use stand-alone Gemzar® therapy as a comparator. But, if early results are an indication, it is not just efficacy that could serve patients well, but if combined with an approved low toxicity due to the reduced chemotherapy dosage, clinicians and patients could seek out the treatment in droves.

Senior Analyst: Robert Goldman
Rob Goldman has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and The Blue and White Fund.

Analyst Certification
I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer
 This Opportunity Research ResearchHot Topics article was prepared for informational purposes only. Goldman Small Cap Research,(a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select product reflects the Firm's internally generated stock ideas while the Opportunityproduct reflects sponsored research reports. It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. While stocks in the Opportunity format may have a higher risk profile, they typically offer greater upside as well. Since April 2012, Goldman Small Cap Research Researchhas been compensated $500 per article by a third party. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. . Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned.Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer:www.goldmanresearch.com